The Use of Tamoxifen to Improve Height Potential in Short Pubertal Boys

@article{Kreher2005TheUO,
  title={The Use of Tamoxifen to Improve Height Potential in Short Pubertal Boys},
  author={Nerissa C. Kreher and Erica A Eugster and R Ravi Shankar},
  journal={Pediatrics},
  year={2005},
  volume={116},
  pages={1513 - 1515}
}
A retrospective chart review of 7 pubertal boys who were treated with tamoxifen was conducted to determine the effects of this therapy on skeletal maturation and predicted adult height. Tamoxifen significantly decreased the rate of skeletal maturation and increased the predicted adult height without negative effects on sexual maturation. Additional evaluation of this therapy is now required to determine if the increase in predicted adult height results in a clinically significant increase in… Expand

Tables and Topics from this paper

Long-term Follow-up of Tamoxifen Treatment in Adolescents with Gynecomastia
Ten pubertal boys treated with tamoxifen for gynecomastia for more than 3 months were evaluated after 2.5-7 years (mean 4.6 years) to determine the side effects of this therapy. We assessed theExpand
Idiopathic short stature: management and growth hormone treatment.
  • J. Wit, E. Reiter, +4 authors P. Cohen
  • Medicine
  • Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
  • 2008
TLDR
In boys with constitutional delay of growth and puberty androgens are effective in increasing height and sexual characteristics, but adult height is unchanged, GH therapy is efficacious in increasingheight velocity and adult height, but the inter-individual variation is considerable. Expand
The effect of tamoxifen on pubertal bone development in adolescents with pubertal gynecomastia
TLDR
Assessment of the effects of tamoxifen on bone mineral density (BMD) and skeletal maturation when used for pubertal gynecomastia concluded that when Pubertal bone development is concerned, tamoxIFen is safe for the treatment of pubertals gyne comastia as neither bone mineralization nor growth potential was affected. Expand
Tamoxifen therapy for the management of pubertal gynecomastia: a systematic review
TLDR
Tamoxifen may be effective for the treatment of pubertal gynecomastia, and it seems safe to use, and Randomized controlled studies are necessary to confirm this indication. Expand
Hormonal Treatment of Idiopathic Short Stature
  • E. Reiter
  • Medicine
  • Hormone Research in Paediatrics
  • 2007
TLDR
Long-term data are needed to assess the behavioral consequences, if any, of GH treatment for children with idiopathic short stature and the use of aromatase inhibitors to slow estrogen-mediated skeletal maturation is a new treatment modality. Expand
Aromatase inhibitors for short stature in male children and adolescents.
BACKGROUND As a result of the essential role of oestrogens in epiphyseal closure, aromatase inhibitors have been trialled as an intervention to improve height outcomes in male children andExpand
Growth Hormone Therapy for Short Stature: Is the Benefit Worth the Burden?
TLDR
Analysis of therapeutic value of rhGH therapy for short stature requires not only examination of effects on adult height but also of the rationale for intervention itself, whether improved height actually leads to better psychosocial outcomes, and how benefits compare to risks and costs. Expand
Induction and Maintenance of Amenorrhea in Transmasculine and Nonbinary Adolescents
TLDR
The physiology of the normal menstrual cycle and the hormonal influences on the endometrium are reviewed, and options for the treatment of persistent bleeding for people both already on testosterone and for those who are either not ready for or who do not desire testosterone are explored. Expand
Oestrogen receptors and linear bone growth
TLDR
It is concluded that SERMs potentially could offer new possibilities to modulate bone growth by specifically targeting different oestrogen receptors within the growth plate. Expand
Safety and clinical outcome of tamoxifen in Duchenne Muscular Dystrophy
TLDR
Tamoxifen-treated patients retained motor and respiratory function, compared with a significant deterioration of age-matched historical control patients receiving corticosteroids only, and warrant a larger clinical trial to substantiate the use of tamoxIFen in Duchenne Muscular Dystrophy. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 11 REFERENCES
A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled trial
TLDR
The findings suggest that if oestrogen action is inhibited in growing adolescents, adult height will increase, and provides a rationale for studies that aim to delay bone maturation in several growth disorders. Expand
Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia.
TLDR
Inhibition of estrogen receptor action in the breast appears to be safe and effective in reducing persistent pubertal gynecomastia, with a better response to raloxifene than to tamoxifen. Expand
Tamoxifen treatment for pubertal gynecomastia
TLDR
Tamoxifen treatment is relatively non-toxic, may be beneficial and it should be considered for pubertal gynecomastia, and the dose was increased in three patients due to poor response. Expand
Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: a multicenter trial.
TLDR
Tamoxifen treatment of precocious puberty in girls with McCune-Albright syndrome results in a reduction of vaginal bleeding and significant improvements in growth velocity and rate of skeletal maturation. Expand
Near final height in pubertal growth hormone (GH)-deficient patients treated with GH alone or in combination with luteinizing hormone-releasing hormone analog: results of a prospective, randomized trial.
TLDR
It is indicated that delaying puberty with LHRH-A in GHD children during treatment with GH increases final height, and this delay in BA maturation produced a significant gain in final height in the group treated with GH+LHRH, which reached - 1.3 +/- 0.5 SD score. Expand
A syndrome of female pseudohermaphrodism, hypergonadotropic hypogonadism, and multicystic ovaries associated with missense mutations in the gene encoding aromatase (P450arom).
TLDR
The cardinal features of this syndrome are a consequence of P450arom deficiency, and the striking delay in bone age at 14 2/12 yr supports the notion that estrogens, in contrast to androgens, are the major sex steroid driving skeletal maturation during puberty. Expand
Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man.
TLDR
Disruption of the estrogen receptor in humans need not be lethal and is important for bone maturation and mineralization in men as well as women. Expand
Tamoxifen and carboplatin for children with low-grade gliomas: a pilot study at St. Jude Children's Research Hospital.
TLDR
Tamoxifen and carboplatin chemotherapy did not result in a significant number of objective responses in children with low-grade gliomas, and the progression-free survival is similar to that of other published series. Expand
Juvenile fibromatosis: hormonal receptors.
TLDR
Should hormonal receptors be present, agents such as tamoxifen conceivably could be employed as part of a post-operative maintenance regimen similar to those protocols applied in the management of hormonally responsive breast cancer. Expand
Radiographic Atlas of Skeletal Development of the Hand and Wrist
The Brush Foundation studies on human growth and development, begun in 1931 and terminated in 1942, have been intensively reviewed and studied by Dr. Greulich and Miss Pyle in the formulation of thisExpand
...
1
2
...